Zelira Therapeutics (ZLD) Stock Price, News & Analysis

Company Overview

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 311,821 shs
• Average Volume: N/A
• Market Capitalization: A$5.79 million
• P/E Ratio: N/A
• Dividend Yield: 8.62%
• Price Target: N/A
• Consensus Rating: N/A

ZLD Stock Analysis - Frequently Asked Questions

How were Zelira Therapeutics' earnings last quarter?

Zelira Therapeutics Limited (ASX:ZLD) announced its quarterly earnings results on Friday, February, 22nd. The company reported $0.00 earnings per share for the quarter. Zelira Therapeutics had a positive trailing twelve-month return on equity of 1,066.85% and a negative net margin of 38,513.04%.

What other stocks do shareholders of Zelira Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zelira Therapeutics investors own include Milestone Pharmaceuticals (MIST), Ovintiv (OVV), SIG (SHI), Allena Pharmaceuticals (ALNA), Alpine Immune Sciences (ALPN), Affiliated Managers Group (AMG) and ARAVIVE (ARAV).

Company Calendar

• Last Earnings: 2/22/2019
• Today: 9/08/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:ZLD
• CIK: N/A
• Web: www.zeldatherapeutics.com
• Phone: 61 8 6558 0886
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($3.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$36.57 million
• Net Margins: -38,513.04%
• Pretax Margin: N/A
• Return on Equity: 1,066.85%
• Return on Assets: -18.87%

Debt

• Debt-to-Equity Ratio: -131.77
• Current Ratio: 0.60
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: A$1.54 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 23.00
• Book Value: A($0.37) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,350,000
• Free Float: N/A
• Market Cap: A$5.79 million
• Optionable: Not Optionable
• Beta: 0.83